Xixi Xiang

ORCID: 0009-0003-0610-5364
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • Multiple Myeloma Research and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • T-cell and Retrovirus Studies
  • Chronic Myeloid Leukemia Treatments
  • Venous Thromboembolism Diagnosis and Management
  • RNA modifications and cancer
  • Cancer, Lipids, and Metabolism
  • Immune cells in cancer
  • Blood Coagulation and Thrombosis Mechanisms
  • Synthesis and bioactivity of alkaloids
  • Synthesis and biological activity
  • Cancer Mechanisms and Therapy
  • Gene expression and cancer classification
  • Quinazolinone synthesis and applications
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Retinoids in leukemia and cellular processes
  • Protein Degradation and Inhibitors
  • Coastal wetland ecosystem dynamics
  • Ferroptosis and cancer prognosis
  • Sepsis Diagnosis and Treatment

Xinqiao Hospital
2012-2024

Army Medical University
2012-2024

Army Medical College
2023

Chongqing Medical University
2023

Second Affiliated Hospital of Chongqing Medical University
2023

Dalian Medical University
2023

State Council of the People's Republic of China
2019

Yunnan University
2013

Gap junctional intercellular communication (GJIC) is typically decreased in malignant tumors. junction not presented between hematopoietic cells but occurred bone marrow stromal (BMSCs). Connexin 43 (Cx43) the major gap (GJ) protein; our previous study revealed that Cx43 expression and GJIC were acute leukemic BMSCs. All-trans retinoic acid (ATRA) increases a variety of cancer has been used to treat promyelocytic leukemia, effects ATRA on BMSCs unknown. In this study, we evaluated potential...

10.1186/s13045-015-0212-7 article EN cc-by Journal of Hematology & Oncology 2015-10-07

T-cell lymphomas (TCLs) are a malignancy characterized by tumor aggression and resistance to traditional chemotherapy. Disruption of the extrinsic cell death pathway is essential for PIM1 serves as crucial modulator in cancers. However, role TCLs remains unclear. In this study, we studied roles established T-lymphoma lines Jurkat HUT-78. CCK-8 assay was conducted evaluate survival flow cytometry performed TCL cells. siRNAs were used knockdown expression c-myc. qRT-PCR mRNA levels c-myc PIM1....

10.1093/abbs/gmy076 article EN Acta Biochimica et Biophysica Sinica 2018-06-08

T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of with poor clinical outcomes and lacks standard treatment regimen. In this study, we assessed the safety efficacy tandem autologous hematopoietic stem cell transplantation (auto-HSCT) strategy for adult T-LBL evaluated prognostic factors affecting survival. 181 Newly-diagnosed patients were enrolled, 89 treated chemotherapy alone, 46 allocated to single auto-HSCT group, auto-HSCT. The median follow-up time was 37 months,...

10.3324/haematol.2019.226985 article EN cc-by-nc Haematologica 2019-11-28

As one of the most renowned traditional Chinese medicine (TCM) prescription, Buyang Huanwu Decoction (BYHWD) can alleviate sepsis induced myocardial injury in LPS septic mice. We find that BYHWD treated mice show significantly prolonged lifespan and display attenuated injury. has both protective therapeutic effects on Here, we is not only capable decreasing circulating proinflammatory cytokines peripheral blood, but also suppressing immune cell infiltration damaged tissue Using flow...

10.2139/ssrn.4049555 article EN SSRN Electronic Journal 2022-01-01

The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety optimized BEAC (adjusted-dose, intermediate-dose cytarabine reduced-dose cyclophosphamide, AD-BEAC) for non-Hodgkin lymphoma (NHL). A total 141 NHL patients received AD-BEAC or a standard-dose (SD-BEAC) from January 2007 to December 2017, 104 were included in study after 1:1 propensity matching. 5-year overall survival (OS) progression free (PFS)...

10.1007/s12185-024-03755-7 article EN cc-by International Journal of Hematology 2024-04-08

Peroxisome proliferator-activated receptor alpha (PPARA) has been suggested as a therapeutic target for chronic lymphocytic leukemia (CLL). However, the underlying molecular mechanism remains largely unclear. In this study, we analyzed DNA next-generation sequencing (NGS) data and clinical information from 86 CLL patients to identify gene markers related treatment-free survival (TFS) length. We then constructed genetic network that includes promoters, treatment targets, TFS-related marker...

10.1155/2023/8456833 article EN cc-by PPAR Research 2023-06-26

Background/Objective: Nearly 30% of patients with advanced-stage Hodgkin lymphoma (HL) are not cured. We should better control tumors initial treatment for advanced stage HL whose interim positron emission tomography/computed tomography (PET/CT) was positive. The objective our study to confirm the superiority autologous hematopoietic stem cell transplantation (ASCT) therapy in these patients.Methods: Eighty-nine III-IV, international prognostic score (IPS) ≥3 and Deauville more than 3° at...

10.1080/16078454.2018.1555024 article EN Hematology 2018-12-15

More than 3 million patients around the world have received clopidogrel, an inhibitor of platelet aggregation, which has largely replaced ticlopidine in clinical practice as it was believed to be devoid side effects caused by ticlopidine. We herein report case a woman who developed myelodysplastic syndrome (MDS) after 1 year treatment with clopidogrel. The absence other plausible causes suggests that her MDS induced Although this is very rare case, clinicians should alert possibility...

10.5414/cp201596 article EN International Journal of Clinical Pharmacology and Therapeutics 2011-12-23

Abstract Background Deep vein thrombosis (DVT) is associated with stroke. Here, we hypothesize that genes DVT may also play roles in the development of Methods firstly conducted large-scale literature based disease-gene relationship data analysis to explore implicated and Further, a mega-analysis was for each these were linked but not stroke, using 11 independent stroke RNA expression datasets (176 cases 102 healthy controls). Then, multiple linear regression (MLR) model employed study...

10.1186/s12881-020-01108-9 article EN cc-by BMC Medical Genetics 2020-10-01

Background: The cause of leukemia, the most common type cancer, remains unknown. Genetic studies have reported more than a thousand genes as being linked to disease.Methods: A total 1,093 leukemia candidate genes, identified from leukemia-gene relations data extracted ResNet 11 Mammalian database and supported by 6,524 references were evaluated. Four network metrics used evaluate individual gene potential relevance leukemia. Gene-set enrichment, sub-network network-connectivity analyses...

10.20900/mo.20160019 article EN Med One 2016-08-23

Abstract Background: The current classification system for diffuse large B-cell lymphoma (DLBCL) cannot fully explain the prognostic differences of DLBCL patients. Cuproptosis is a newly discovered programmed cell death which depends on copper ions. In this study, model based cuproptosis-related genes was constructed using public database. Methods and materials: COX regression analysis performed training set-GSE31312 to construct genes, validation set-GSE181063 used verify model. GSEA...

10.21203/rs.3.rs-2894988/v1 preprint EN cc-by Research Square (Research Square) 2023-05-11

Topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical Background: Time-to-first treatment (TTFT) may be an important endpoint for treatment-naive chronic (CLL) patients since it can help to idntify early drives of disease. TTFT is not affected by treatment-induced clonal evolution, which reflects the intrinsic biology disease heterogeneity better[1-3]. Aims: Prognostic analysis gene mutations in newly diagnosed CLL who have a shorter TTFT, tried find more predictive driving...

10.1097/01.hs9.0000974632.93232.bb article EN cc-by-nc-nd HemaSphere 2023-08-01

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The current classification system for diffuse large B-cell (DLBCL) cannot fully explain the prognostic differences of DLBCL patients. Cuproptosis is a newly discovered programmed cell death which depend on copper ions. However, potential role cuproptosis in prognosis patients remains unclear. Aims: In this study, model based cuproptosis-related genes was constructed using public database. target compounds that may act related...

10.1097/01.hs9.0000971660.44958.77 article EN cc-by-nc-nd HemaSphere 2023-08-01

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially refractory acute lymphoblastic However, they are relatively expensive, limiting their widespread use. For lacking matched sibling donors, haploidentical donors an option. This study analyzed clinical outcomes of 119 leukemia who underwent...

10.46701/bg.2023012022039 article EN cc-by Blood&Genomics 2023-01-01

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Copy number abnormalities (CAA) is an important prognosis factor for multiple myeloma (MM). The detection rate of existing methods low the chromosomal variation cannot be obtained comprehensively. LeukoPrint a novel shallow whole-genome sequencing (sWGS) based approach to profile CNA may make up deficiencies traditional techniques improve chromosome variation. Aims: To observe clinical application sWGS in detecting...

10.1097/01.hs9.0000975168.62819.31 article EN cc-by-nc-nd HemaSphere 2023-08-01

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially refractory acute lymphoblastic However, they are relatively expensive, limiting their widespread use. For lacking matched sibling donors, haploidentical donors an option. This study analyzed clinical outcomes of 119 leukemia who underwent...

10.46701/bg.2023022022039 article EN cc-by Blood&Genomics 2023-01-01
Coming Soon ...